ライフサイエンスコーパス: complete response

1 se or better; 14.1% and 4.3% had a stringent complete response).

2 Overall response rates were 76% (4 complete responses).

3 ve a response, with 40% continuing to have a complete response.

4 ntional, DW, and DCE MR images to identify a complete response.

5 h a predominant expansion in patients with a complete response.

6 ed to brentuximab vedotin, and 7 exhibited a complete response.

7 7.2% [95% CI 66.1-86.6]) patients achieved a complete response.

8 ients, who also tend to achieve pathological complete response.

9 including one patient (5%) with a prolonged complete response.

10 e response (20%), including 1 with a durable complete response.

11 lts in up to 49% of patients with a clinical complete response.

12 There was 1 complete response.

13 , including 12 patients (26%) who achieved a complete response.

14 nts who completed BV + AVD + ISRT achieved a complete response.

15 t whether a patient will have a pathological complete response.

16 The primary end point was pathological complete response.

17 The primary end point is pathological complete response.

18 deeper than those conventionally defined as complete response.

19 oresis assays may lead to underestimation of complete response.

20 ate dehydrogenase and 63% in patients with a complete response.

21 rate by IWG criteria, with 62.5% achieving a complete response.

22 a CMR, 6 responded to BR but none achieved a complete response.

23 ved D + T 150/2 improved from a partial to a complete response.

24 cts, voluntary withdrawal by the patient, or complete response.

25 (29%) of 31 patients achieved a pathological complete response.

26 ll response and 49 (40%) patients achieved a complete response.

27 s cancer therapies from achieving stable and complete responses.

28 s, including four partial responses and five complete responses.

29 R was 23% (12 of 52), including four ongoing complete responses.

30 ficacy, most patients do not achieve durable complete responses.

31 onses, 4 complete responses, and 3 stringent complete responses.

32 nd 2 (13%) had specimens that had pathologic complete responses.

33 six patients (75.0%), including four of five complete responses.

34 sus 33% of high-grade tumors (grade 3 or 4) (complete response, 0%; partial response, 33%; SD or DP,

35 patients (stringent complete response, 12%; complete response, 10%; very good partial response, 28%;

36 -94) among all evaluable patients (stringent complete response, 12%; complete response, 10%; very goo

37 all response rate (ORR) to first KI was 62% (complete response 14%).

38 e rate (42% vs. 53%), the median duration of complete response (18.0 months vs. 42.1 months), the med

39 a dose of 10 mg per kilogram, 5 (23%) had a complete response, 2 (9%) had a partial response, and 6

40 rall response rate was 81%, with 8 stringent complete responses (25%), 3 complete responses (9%), and

41 The objective response rate was 21% (complete response = 4 [8%]; partial response = 7 [13%])

42 -term treatment response in 87% of patients (complete response, 49%; partial response, 38%; stable di

43 % was observed, including 11 (23%) composite complete responses, 5 of which were minimal residual dis

44 reatment, patients with HT had less frequent complete response (50.3% v 67.4%; P = .03) and more dise

45 On intent to treat, 85% responded (3% complete response, 7% very good partial response, 58% pa

46 (88%; 95% CI, 81% to 93%), of whom 88 had a complete response (70%; 95% CI, 61% to 77%).

47 Results Clinical response (complete response, 78% v 76%; partial response, 5% v 9%)

48 -CHOP with an overall response rate of 100% (complete responses 89%).

49 with 8 stringent complete responses (25%), 3 complete responses (9%), and 9 very good partial respons

50 the 17 patients with vitiligo, 3 (18%) had a complete response, 9 (53%) had a partial response, 3 (18

51 Complete response affects 1% of patients with HCC who ar

52 portion of patients achieving a pathological complete response after combination cytotoxic chemothera

53 Overall, 84% of treated patients achieved a complete response after first-line therapy.

54 restricted radiotherapy to patients without complete response after HCT-ASCT.

55 Despite high rates of complete response after initial immunochemotherapy follo

56 netic resonance (MR) imaging with pathologic complete response after preoperative combined chemothera

57 be sufficient treatment for patients with a complete response after rituximab induction.

58 Complete response after up-front treatment and frontline

59 Partial or complete responses against targeted viruses occurred in

60 Patients who achieved total pathological complete response (all groups combined) had longer progr

61 There were 3 complete responses, all among patients with PTCL.

62 tion of patients who achieved a pathological complete response, analysed by intention to treat.

63 I 46-79), with two (6%) patients achieving a complete response and 21 (58%) a partial response.

64 confirmed objective response, including one complete response and 21 partial responses.

65 uding 25 (51%) of 49 patients who achieved a complete response and 28 (57%) of 49 patients who achiev

66 esponse rate was 52% (9 of 17) (6% [1 of 17] complete response and 46% [8 of 17] partial response), w

67 , cohort 1; 20, cohort 2); 49 (75%) achieved complete response and 64 proceeded to ASCT.

68 Eleven patients (44%) achieved a complete response and 7 (28%) achieved a partial respons

69 ty curve, and DW imaging are associated with complete response and incomplete response and could pote

70 esponse (calculated as the combined rates of complete response and partial response).

71 ed by watch and wait who achieved a clinical complete response and those who had surgical resection (

72 ed theranostic PRIT regimen that led to 100% complete responses and 100% cures without any treatment-

73 nts (17%; 95% CI 11-24), including nine (6%) complete responses and 18 (11%) partial responses.

74 ents had an objective responses, including 4 complete responses and 18 partial responses, which were

75 21.9-43.1]) of 88 patients, including eight complete responses and 20 partial responses.

76 There were 7 complete responses and 8 partial responses to combinatio

77 Overall response rate was 77% (15 complete responses and 8 partial responses) in 30 evalua

78 treated with (90)Y-daclizumab there were 14 complete responses and nine partial responses; 14 patien

79 Seven complete responses and one partial tumor response are on

80 There were two complete responses and seven partial responses.

81 patients achieved an objective response (two complete responses and three partial responses).

82 eview was 18.2% (95% CI, 8.2% to 32.7%; five complete responses and three partial responses).

83 t support the primary endpoint (pathological complete response) and suggest that neoadjuvant pertuzum

84 e interval [CI], 35 to 76); 4 patients had a complete response, and 10 had a partial response.

85 Thirty-four patients had complete response, and 12 had residual disease at the en

86 ith 22 (44%, 30.0-58.7) patients achieving a complete response, and 22 (44%, 30.0-58.7) a partial res

87 on approval of ibrutinib; 7 (64%) achieved a complete response, and 3 (27%) achieved a partial respon

88 ol, after starting sorafenib, at the time of complete response, and at least 1 month after treatment

89 ie, confirmed complete response, unconfirmed complete response, and partial response) at the end of i

90 distant relapse-free survival, pathological complete response, and residual cancer burden in the Not

91 including 13 very good partial responses, 4 complete responses, and 3 stringent complete responses.

92 esponse of a patient using pCR (pathological complete response) as the measure of response.

93 he per-protocol population, was pathological complete response, assessed via specimens obtained durin

94 The rate of complete response at 6 months was 33% in cohort 1, 26% i

95 The primary endpoint was complete response at day 30 after HCT-ASCT in all regist

96 ma achieved durable objective responses (two complete responses at 120 mg once a day, and one partial

97 or PFS, whereas DHL and partial response ( v complete response) at transplant were associated with in

98 se for mBCC was 33.6% (95% CI, 33.1%-34.2%); complete response averaged 3.9% (95% CI, 3.3%-4.4%).

99 hted average of 64.7% (95% CI, 63.7%-65.6%); complete response averaged 31.1% (95% CI, 30.4%-31.8%).

100 Interestingly, complete response but not partial response to MSCs was a

101 A clinical complete response (cCR) rate of 81 (56%) was observed in

102 showed a significantly improved pathological complete response compared with those given trastuzumab

103 esponse, the following categories were used: complete response (complete resolution of proven or susp

104 response, the following criteria were used: complete response (complete resolution of symptoms attri

105 The primary endpoint was composite complete response (complete response, complete response

106 ry endpoint was composite complete response (complete response, complete response with incomplete pla

107 9 [60%] of 48) patients, including stringent complete response/complete response (4 [8%]), very good

108 onally, they suggest that total pathological complete response could be an early indicator of long-te

109 patients (71%) responded; 18 (40%) achieved complete response (CR) and 14 (31%) partial response (PR

110 est response among 21 evaluable patients was complete response (CR) in 2 (9.5%) and stable disease in

111 ly in patients who had achieved conventional complete response (CR) in 5 studies for PFS (n = 574) an

112 r activity in metastatic melanoma, including complete response (CR) in about 15% of patients.

113 Of 7 patients with relapsed HL, 1 entered complete response (CR) lasting more than 2.5 years after

114 ORR (67% vs 49%, P = .08) and complete response (CR) or CR with incomplete cytopenia r

115 n elderly patients with DLBCL who achieved a complete response (CR) or partial response (PR) to R-CHO

116 urvival (EFS), treatment discontinuation, no complete response (CR) or unconfirmed complete response

117 The primary end point was complete response (CR) rate after four cycles of therapy

118 int was the 2007 international working group complete response (CR) rate after induction.

119 The overall complete response (CR) rate was 82.9% for RS and 82.5% f

120 dary outcomes were based on response (R) and complete response (CR) rates as defined by the American

121 The complete response (CR) rates by patient or by tumor were

122 Observed day +100 complete response (CR) rates equaled 25.5% for defibroti

123 ential trials improved objective partial and complete response (CR) rates.

124 Patients with less than a complete response (CR) to AV-PC received 21-Gy involved-

125 Patients who achieved a complete response (CR) to brentuximab vedotin (N = 34) h

126 ient (ADC) measurements on the assessment of complete response (CR) to neoadjuvant combined chemother

127 ght chain amyloidosis (AL) fail to achieve a complete response (CR) to standard light chain suppressi

128 Patients with a complete response (CR), as assessed by the investigator

129 iferative syndrome (ALPS) achieved a durable complete response (CR), including rapid improvement in a

130 were treated until progression, toxicity, or complete response (CR).

131 Patients with complete response (CR)/CR with incomplete count recovery

132 ofovir-unresponsive patients and resulted in complete responses (CR) despite significant lymphopenia

133 rate (partial response [PR] + very good PR + complete response [CR] + stringent CR).

134 -T cell infusion, the overall response rate (complete response [CR] and/or partial response [PR]) by

135 hieving complete resolution of all symptoms (complete response, CR) varied between 8% and 83%.

136 fter 1 blinatumomab cycle was 43%, including complete responses (CRs) in 19%.

137 el, ifosfamide, and cisplatin (TIP) achieved complete responses (CRs) in two thirds of patients with

138 remissions; however, the median responses of complete responses (CRs) with the latter were only 6.7 m

139 L overall response rate, 58% (n = 31) with 6 complete responses (CRs); relapsed/refractory CLL, 56% (

140 , the overall response rate was 38.2% with 5 complete responses (CRs; 14.7%) and 8 very-good-partial

141 on, no complete response (CR) or unconfirmed complete response (CRu) after eight cycles, progression,

142 was the proportion of patients who achieved complete response (defined as no vomiting, no retching,

143 number of patients who achieved a composite complete response did not differ between dose groups or

144 ients discontinued sorafenib after achieving complete response due to adverse events, patient decisio

145 ) has been undervalued due to the absence of complete responses, even though patients who develop ear

146 patients who achieved an overall response, a complete response, event-free survival at 12 months and

147 lar response (nine of ten patients who had a complete response, five of 20 who had a partial response

148 tients developed progressive disease after a complete response for 38 months and stable disease for 1

149 ribe the profile of the patients who achieve complete response for identifying factors related to thi

150 assess the effects on rates of pathological complete response (i.e., absence of residual cancer in t

151 49 patients achieved a response, including a complete response in 25 (51%) of 49 patients.

152 % of patients (very good partial response or complete response in 29%), as well as improved survival.

153 Pathologic complete response in HER2-positive breast cancer is asso

154 75), irinotecan, and vincristine can lead to complete response in multiple rhabdomyosarcoma orthotopi

155 Oncological Outcomes after Clinical Complete Response in Patients with Rectal Cancer (OnCoRe

156 s childhood STRA is heterogeneous and that a complete response in symptoms and inflammatory and physi

157 ertuzumab increases the rate of pathological complete response in the preoperative context and increa

158 therapy, the estimated rates of pathological complete response in the triple-negative population were

159 nograft and inhibit tumor growth, generating complete responses in the majority of treated animals.

160 sation was allowed for patients who achieved complete response (including complete response with inco

161 Pathological complete responses increased from 13.7% to 19.5% in the

162 portion of patients achieving a pathological complete response is small.

163 t best clinical method to predict pathologic complete response is SUVmax in (18)F-FDG PET/CT imaging.

164 sponse (k=0.96, percent agreement=98.1%) and complete response (k=0.87, Percent agreement=93.3%).

165 We also included patients with a clinical complete response managed by watch and wait between Marc

166 ring hospitals and 31 of whom had a clinical complete response, managed by watch and wait.

167 Although some MGUS clones exhibited a complete response, many did not respond, which suggests

168 nd the 12 with SMM achieving at least a near-complete response, MRD negativity was found in 28 of 28

169 onse rate was 30% (partial response, n = 19; complete response, n = 2), the median response duration

170 p imaging, 11 patients had responses to TAE (complete response, n = 6; partial response, n = 5) and 1

171 usea prevention was the primary end point; a complete response (no emesis and no use of rescue medica

172 t was the proportion of patients achieving a complete response (no emesis or use of rescue medication

173 The primary end point was pathologic complete response (no invasive carcinoma in breast or ax

174 Complete responses occurred in 4 patients with extramedu

175 e rate was 88%, with a mean (SD) duration of complete response of 14.43 (6.6) months.

176 One patient achieved complete response of numerous hepatic metastases, curren

177 e for MALT lymphomas (137 patients) reported complete responses of between 4.4% and 13%.

178 ruption in all 3 cases, and all patients had complete responses of their primary cancers.

179 e to below the measurable level and showed a complete response on imaging.

180 with a major pathologic response (pathologic complete response or <5% residual cancer cells) were eva

181 nse or better (59.2% vs. 29.1%, P<0.001) and complete response or better (19.2% vs. 9.0%, P=0.001).

182 gh- or standard-risk cytogenetics achieved a complete response or better with KRd vs Rd (29.2% vs 5.8

183 Among patients with a complete response or better, 29% were MRD negative at a

184 or response in these respective groups had a complete response or better.

185 % of patients in the respective groups had a complete response or better; 14.1% and 4.3% had a string

186 even of 15 evaluable patients (47%) achieved complete response or complete response with incomplete c

187 centage of patients who achieved a confirmed complete response or partial response per Response Evalu

188 y endpoint was confirmed objective response (complete response or partial response) assessed accordin

189 tive response rate (best overall response of complete response or partial response) in patients with

190 8 to 8.3 months); and clinical benefit rate (complete response + partial response + stable disease >/

191 11.3) months, and the clinical benefit rate (complete response + partial response + stable disease >/

192 Complete response, partial response, and stable disease

193 Overall response will be defined as complete response, partial response, minor response, sta

194 %) of 37 patients, the target lesions showed complete response, partial response, or stable disease (

195 erall lesion assessment at month 9 showing a complete response, partial response, or stable disease a

196 atients with an overall lesion assessment of complete response, partial response, or stable disease w

197 A reliable prediction of a pathologic complete response (pathCR) to chemoradiotherapy before s

198 highest in patients who achieved pathologic complete response (pCR) (P < 0.0001 and P < 0.0001, resp

199 (P = 0.04), and the absence of a pathologic complete response (pCR) (P = 0.01).

200 Importance: Pathologic complete response (pCR) after neoadjuvant chemoradiother

201 east cancers were associated with pathologic complete response (pCR) after neoadjuvant chemotherapy a

202 pathologic response, considering pathologic complete response (pCR) as the complete absence of any r

203 ird of patients with TNBC achieve pathologic complete response (pCR) from standard-of-care anthracycl

204 ssociated with a better rate of pathological complete response (pCR) in rectal cancer.

205 ssue optical index (TOI), predict pathologic complete response (pCR) in women undergoing breast cance

206 cer (TNBC) have poor outcome when pathologic complete response (pCR) is not reached after neoadjuvant

207 The long-term effect of axillary pathologic complete response (pCR) on survival among women with bre

208 Purpose To determine the pathologic complete response (pCR) rate in estrogen receptor (ER) -

209 R2 blockade resulted in increased pathologic complete response (pCR) rates compared with each targete

210 R2 blockade resulted in increased pathologic complete response (pCR) rates compared with each targete

211 xane, and bevacizumab increases pathological complete response (pCR) rates in patients with triple-ne

212 in Early Breast Cancer) compares pathologic complete response (pCR) rates of T-DM1 versus trastuzuma

213 Although a pathologic complete response (pCR) remains an important positive pr

214 A pathologic complete response (pCR; no invasive or in situ cancer) o

215 Purpose A pathologic complete response (pCR; ypT0N0) of a rectal tumor after

216 The primary endpoint was tumor response (complete response plus partial response) at 3 mo.

217 lacebo group, and the corresponding rates of complete response plus very good partial response were 4

218 f patients who achieved an overall response (complete responses plus partial responses plus minor res

219 lesion AD threshold value maximizing correct complete response prediction was 90 Gy for remnants and

220 Two with minimal residual disease-positive complete response progressed after 24 months off therapy

221 and carfilzomib treatment appear to improve complete response, progression-free survival, and overal

222 Both arms yielded similar complete response rate (42% and 40%), median PFS (32 mon

223 improved in the VR-CAP group, including the complete response rate (42% vs. 53%), the median duratio

224 Here, a clinically meaningful initial complete response rate (for carcinoma in situ) or recurr

225 Primary end points were the complete response rate (in the Italian trial) and the ov

226 were associated with a significantly better complete response rate (P = .04) and progression-free su

227 , the overall response rate was 89%, and the complete response rate 77%.

228 Sixty-two patients were enrolled; the complete response rate among all treated patients (n = 6

229 Our objective was to formally assess the complete response rate at 30 months (CR30) after initiat

230 us, the goal of this study was to assess the complete response rate in a retrospective cohort of HCC

231 ORR was 37.5% with a complete response rate of 12.5%, median progression-free

232 rmed objective response rate was 62%, with a complete response rate of 33% per immune-related respons

233 The objective response rate was 82%, and the complete response rate was 54%.With a median follow-up o

234 response rate was 23% (95% CI 16 to 31), the complete response rate was 9% (n=11), and 19 of 27 respo

235 n treating LyP (overall response rate, 100%; complete response rate, 58%), but its use should be rese

236 DLBCL, the objective response rate was 26% (complete response rate, 7%) to the next line of therapy,

237 The complete-response rate was also significantly increased

238 y improved nausea prevention, as well as the complete-response rate, among previously untreated patie

239 and palonosetron was associated with higher complete response rates (no emesis and no rescue medicat

240 r 2 (HER2) targeting can increase pathologic complete response rates (pCRs) to neoadjuvant therapy an

241 f adoptive cell therapies (ACT) in melanoma, complete response rates remain relatively low and outcom

242 d with palonosetron 0.50 mg) produced higher complete response rates than palonosetron alone among pa

243 Given the high rates of complete response seen in patients with multiple myeloma

244 ts who achieved well-controlled urticaria or complete response sustained response throughout the trea

245 antly more patients achieving a pathological complete response than HER2-targeted chemotherapy plus H

246 ly to result in higher rates of pathological complete response than standard chemotherapy with trastu

247 apy resulted in higher rates of pathological complete response than standard therapy alone specifical

248 challenging clinical situations who showed a complete response to (225)Ac-PSMA-617 therapy.

249 NRAS and HRAS mutations showed a partial and complete response to cetuximab, respectively.

250 Only 2 of these 17 patients achieved complete response to GVHD treatment, and 14 of 17 requir

251 The patient had a complete response to high-dose chemotherapy and no major

252 response, we constructed a model to predict complete response to nCRT in EC based on pretreatment cl

253 p = 0.04) were associated with pathological complete response to neoadjuvant chemotherapy in ER-nega

254 In this near-complete response to PD-1 blockade in a mesenchymal tumo

255 ll or disease-free survival and a pathologic complete response to preoperative anthracycline therapy

256 al, or fallopian tube cancer, and a clinical complete response to primary platinum-based chemotherapy

257 Ninety-five percent of our cohort achieved a complete response to recombinant IL-1 receptor antagonis

258 A small number of cases of complete response to sorafenib treatment have now been r

259 Patients with pathological complete or near-complete response (tumor regression grade 1-2) were clas

260 ly Urticaria Activity Score [UAS7] </= 6) or complete response (UAS7 = 0).

261 ays (UAS7) 6: 51.9% vs. 11.3%; P<0.0001) and complete response (UAS7=0: 35.8% vs. 8.8%; P<0.0001) ver

262 response was seen in five patients (13.5%), complete response unconfirmed in three (8%), and partial

263 stage 2 was overall response (ie, confirmed complete response, unconfirmed complete response, and pa

264 Ten Spanish centers submitted cases of complete response under sorafenib.

265 M1 clones had a response to therapy (either complete response, very good partial response, partial r

266 gic response (14% very good partial response/complete response [VGPR/CR]), with median OS not reached

267 se after completion of salvage chemotherapy (complete response vs partial response vs stable disease)

268 our historical cohort, in which the rate of complete response was 10% and the overall response rate

269 cer, the mean estimated rate of pathological complete response was 56% (95% Bayesian probability inte

270 A pathological complete response was achieved by 99 (44.4%) of 223 pati

271 In the low-dFLC group, complete response was associated with a significant adva

272 A complete response was defined as normalisation of all af

273 Complete response was defined as zero lesions, and parti

274 Complete response was defined by decrease of serum creat

275 The percentage of patients with a complete response was higher in the transplantation grou

276 The incidence of pathologic complete response was low (<10%).

277 A complete response was observed in 83% (five of six) of A

278 the cell dose-escalation phase, an objective complete response was observed in a patient with metasta

279 Complete response was seen in five patients (13.5%), com

280 The primary endpoint (pathological complete response) was previously reported; secondary en

281 Patients who had a clinical complete response were offered management with the watch

282 ponses were observed in 53% of patients, and complete responses were achieved in 21% of patients.

283 linded independent central review: confirmed complete responses were achieved in six (3%) patients an

284 to excessive tumor burden, whereas 10 of 10 complete responses were observed for the DOTA-PRIT-treat

285 The two complete responses were ongoing 22 and 15 months after t

286 reatment responses, that is, no, partial, or complete response, were assessed by use of the urticaria

287 ory to conventional chemotherapy who achieve complete response when treated with the tyrosine kinase

288 Induction of a clinical complete response with chemoradiotherapy, followed by ob

289 proportion of patients achieved pathological complete response with CT-P6 (116 [46.8%; 95% CI 40.4-53

290 The association of complete response with early dermatologic reactions supp

291 acute myeloid leukaemia achieved a composite complete response with guadecitabine at all drug doses a

292 patients (47%) achieved complete response or complete response with incomplete count recovery.

293 ts who achieved complete response (including complete response with incomplete marrow recovery) or ne

294 sponse with incomplete platelet recovery, or complete response with incomplete neutrophil recovery re

295 posite complete response (complete response, complete response with incomplete platelet recovery, or

296 owed by treatment with CTL019 cells led to a complete response with no evidence of progression and no

297 drew consent after in cycle 1 and attained a complete response with R-CHOP alone.

298 hree syngeneic mouse tumor models, including complete responses with protective immunity.

299 There was no evidence of improvement in complete response within 1 year reported in 27 (46.6%) p

300 mber of patients who achieved a pathological complete response (ypT0/is, ypN0), between groups in the